Division of Nephrology, Department of Medicine, and.
Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, Maryland.
Clin J Am Soc Nephrol. 2017 Nov 7;12(11):1787-1794. doi: 10.2215/CJN.02560317. Epub 2017 Sep 28.
Causes of CKD differ in prognosis and treatment. Metabolomic indicators of CKD cause may provide clues regarding the different physiologic processes underlying CKD development and progression.
DESIGN, SETTING, PARTICIPANTS & MEASUREMENTS: Metabolites were quantified from serum samples of participants in the Modification of Diet in Renal Disease (MDRD) Study, a randomized controlled trial of dietary protein restriction and BP control, using untargeted reverse phase ultraperformance liquid chromatography tandem mass spectrometry quantification. Known, nondrug metabolites (=687) were log-transformed and analyzed to discover associations with CKD cause (polycystic kidney disease, glomerular disease, and other cause). Discovery was performed in Study B, a substudy of MDRD with low GFR (=166), and replication was performed in Study A, a substudy of MDRD with higher GFR (=423).
Overall in MDRD, average participant age was 51 years and 61% were men. In the discovery study (Study B), 29% of participants had polycystic kidney disease, 28% had glomerular disease, and 43% had CKD of another cause; in the replication study (Study A), the percentages were 28%, 24%, and 48%, respectively. In the discovery analysis, adjusted for demographics, randomization group, body mass index, hypertensive medications, measured GFR, log-transformed proteinuria, and estimated protein intake, seven metabolites (16-hydroxypalmitate, kynurenate, homovanillate sulfate, N2,N2-dimethylguanosine, hippurate, homocitrulline, and 1,5-anhydroglucitol) were associated with CKD cause after correction for multiple comparisons (<0.0008). Five of these metabolite associations (16-hydroxypalmitate, kynurenate, homovanillate sulfate, N2,N2-dimethylguanosine, and hippurate) were replicated in Study A (<0.007), with all replicated metabolites exhibiting higher levels in polycystic kidney disease and lower levels in glomerular disease compared with CKD of other causes.
Metabolomic profiling identified several metabolites strongly associated with cause of CKD.
慢性肾脏病(CKD)的病因在预后和治疗上存在差异。CKD 病因的代谢组学指标可能为 CKD 发展和进展所涉及的不同生理过程提供线索。
设计、地点、参与者及测量:采用靶向反向高效液相色谱串联质谱定量法,从参与改良肾脏病饮食研究(MDRD)的参与者的血清样本中定量检测代谢物。MDRD 是一项关于饮食蛋白限制和血压控制的随机对照试验。已知非药物代谢物(=687)经对数转换后,用于分析与 CKD 病因(多囊肾病、肾小球疾病和其他病因)的相关性。发现阶段在 MDRD 的子研究 B 中进行,研究对象的肾小球滤过率(GFR)较低(=166),复制阶段在 MDRD 的子研究 A 中进行,研究对象的肾小球滤过率较高(=423)。
在 MDRD 中,参与者的平均年龄为 51 岁,61%为男性。在发现研究(研究 B)中,29%的参与者患有多囊肾病,28%患有肾小球疾病,43%患有其他病因的 CKD;在复制研究(研究 A)中,相应的百分比分别为 28%、24%和 48%。在发现分析中,经人口统计学、随机分组、体重指数、高血压药物、测量的肾小球滤过率、对数转换蛋白尿和估计的蛋白质摄入量调整后,7 种代谢物(16-羟棕榈酸酯、犬尿氨酸、高香草酸硫酸盐、N2,N2-二甲基鸟苷、马尿酸、同型瓜氨酸和 1,5-脱水葡萄糖醇)在多重比较校正后与 CKD 病因相关(<0.0008)。这 5 种代谢物关联(16-羟棕榈酸酯、犬尿氨酸、高香草酸硫酸盐、N2,N2-二甲基鸟苷和马尿酸)在研究 A 中得到了复制(<0.007),与其他病因的 CKD 相比,所有复制的代谢物在多囊肾病中水平较高,在肾小球疾病中水平较低。
代谢组学分析鉴定出与 CKD 病因强烈相关的多种代谢物。